Previous in vivo and in vitro studies from our laboratory have revealed a line of pharmacological evidence supporting histamine H3 receptor(s) involvement in the control of gastric acid secretion. We have recently extended our studies to the human gastric tumoral cell HGT-1. This cell was found to contain an H3 receptor inhibiting basal and carbachol-stimulated inositol phosphate formation. Furthermore, we were able to solubilize and affinity-purify this receptor in the form of a single 70 kDa protein. These findings are the first biochemical description of the H3 receptor subtype and the first direct demonstration that this subtype can occur on a non-neural cell. Furthermore, they provide a molecular basis to explain its suggested inhibitory role in gastric physiology.
INTRODUCTION
The novel "H3" histamine receptor subtype was originally characterized on brain histaminergic nerves as an autoreceptor downregulating histamine synthesis and release [1] . The localization of this receptor was, however, rapidly extended to serotoninergic, cholinergic, and non-cholinergic fibers, in brain as well as in peripheral tissues such as airways, lung, and intestine [2, 3] .
We summarize here recent studies from our laboratory, supporting the hypothesis that H3 receptors are very likely to be involved in the control of gastric acid secretion. Furthermore, we report preliminary results on biochemical and functional characterization of a gastric H3 receptor in the human gastric cell line HGT-1.
PHARMACOLOGICAL EVIDENCE
The first evidence for a gastric H3 receptor subtype came from in vivo studies carried out in our laboratory on fistula cats by Hervatin et al. [4] and Bado et al. [5] . These studies showed that stimulation of acid secretion by meal or pentagastrin was potently and dose-dependently inhibited by the specific H3 agonist Rao-methylhistamine (Ra-MeHA). Furthermore, this inhibition was itself inhibited by the specific H3 antagonist thioperamide (Figs. 1, 2) . The fact that Ra-MeHA inhibited pentagastrin stimulation suggests that the putative H3 receptor(s) should be located downstream of the gastrin receptor. Furthermore, an extrinsic cholinergic vagal mediation is apparently excluded, since similar findings were observed for the main stomach and the denervated Heidenhain pouch.
The possibility that Ra-MeHA inhibition of (penta)gastrin stimulation could be mediated by histamine cell H3 receptors was investigated by Sandvik et al. on the isolated rat stomach [6] . These gastrin-stimulated vascular histamine release in a ranitidine-insensitive manner (Fig.  2 ). This finding is consistent with the presence of an H3 autoreceptor on the histamine-secreting cell, in agreement with the report of H3 autoreceptors on brain histaminergic nerves [1] and with the early suggestion by H'akanson et al. that histamine inhibits its own synthesis and release in the gastric mucosa [7] . The intervention of an H2-type receptor was previously postulated because the stimulation of gastric mucosal histamine release, evoked by pentagastrin injection in the rat, was reported to be increased after infusion of metiamide, burimamide, or cimetidine [8, 9] . These findings, which contrast with the lack of effect of ranitidine in the in vitro [5] . Thiop [10] . study of Sandvik et al. [6] , might be, however, inherent in the in vivo situation and the doses used.
Evidence for H3modulation of other mediators of acid secretion was investigated on the same experimental model by Moizo et al. [10] . These studies demonstrated that Ra-MeHA strongly potentiated carbachol-induced vascular gastrin release and that this effect was totally suppressed by thioperamide. Such a finding might be interpreted as evidence for an H3 receptor on the gastrin cell. Since in this study, Rea-MelA concomitantly reversed carbachol inhibition of somatostatin release, however, gastrin release potentiation could be secondary to this effect. Thus, in addition to its putative location on the histamine-secreting cell, the H3 receptor could also occur on other gastric endocrine cells, such as gastrin and somatostatin cells.
In an attempt to gain a deeper insight into the role of H3receptors in the cellular mechanisms regulating acid secretion, we carried out further studies on isolated rabbit gastric glands [11] . We found that Ret-MeHA inhibited and thioperamide enhanced basal histamine release (Fig. 3) , in agreement with the suggested existence of an inhibitory H3 receptor on gastric histamine cells. In addition, thioperamideenhanced histamine release was accompanied by the stimulation of 14C-aminopyrine accumulation by the glands. Thioperamide stimulation of 14C-aminopyrine accumulation was still present, however, after blockade of the parietal cell H2 receptor by ranitidine (Fig. 3) . Moreover, Ra-MeHA also inhibited carbachol-and even histaminestimulated 14C-aminopyrine accumulation (Fig. 4) . These findings do not conflict with the presence of an H3 receptor on histaminocytes but argue strongly for the additional presence of an H3 receptor on the parietal cell itself (Fig. 4) .
BIOCHEMICAL EVIDENCE
A direct demonstration of gastric H3 receptor(s) was recently attempted in our laboratory, using the human gastric tumoral cell HGT-1. The great suitability of this model for the study of gastric acid secretion receptors, particularly histamine H2 and somatostatin receptors had been previously shown [12, 13, 14] (Fig. 5 ) [15] . These findings are the first direct evidence for the existence of H3 receptors as a distinct biochemical entity and for the occurrence of this receptor on a non-neural cell. They further support the hypothesis that this novel receptor subtype is negatively coupled to phosphatidylinositol turnover, a signaling pathway consistent with its general inhibitory action, as reported in the above studies. 
